Inclusion Criteria : 
  -  Histology : Part 1 : Metastatic castration - resistant prostate cancer ( mCRPC ) with histologic confirmation of adenocarcinoma.  Adenocarcinoma with small - cell or neuroendocrine features is allowed.  mCRPC is defined by prostate Cancer Working Group ( PCWG ) 3 criteria.  Part 2 : mCRPC as defined above or pathologically confirmed metastatic renal cell carcinoma ( RCC ) as defined by world health organization ( WHO ) 
     2016 Classifications
  -  Measurable or evaluable disease : Part 1 : Either measurable or evaluable disease for prostate cancer.  Part 2 : At least one measurable lesion as per RECIST v1.1. 
  -  Evidence of disease progression on prior therapy that requires a new line of treatment
  -  Participants with accessible lesions enrolled in selected pharmacokinetic ( PK )  / pharmacodynamics ( PD ) cohorts and in Part 2 must agree to undergo the mandatory fresh tumor biopsies , unless collection of the biopsy presents a safety risk
Exclusion Criteria : 
  -  At least 2 weeks between prior anticancer treatment ( including radiotherapy ) discontinuation and the first dose of study drug , and toxicities have returned to Grade less than or equal to (  <  =  ) 1 or baseline
  -  Prior treatment with prostate - specific membrane antigen ( PSMA )  - targeted therapy except for PSMA - targeted vaccine is permitted
  -  Solid organ or bone marrow transplantation
  -  Seizure or known condition that may predispose to seizure or intracranial masses
  -  Other active malignancy requiring systemic treatment <  = 12 months prior to enrollment